February 2, 2021Journal of Clinical OncologyOpen Access

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

View Full Paper

Ask AI

Bookmark

Abstract

First-line pembrolizumab monotherapy showed promising antitumor activity in nccRCC. The safety profile was similar to that observed in other tumor types.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

McDermott et al. (2021) studied this question.

synapsesocial.com/papers/69dc34d445b398e6439f558d https://doi.org/10.1200/jco.20.02365

View Full Paper

Ask AI

Bookmark

Abstract

First-line pembrolizumab monotherapy showed promising antitumor activity in nccRCC. The safety profile was similar to that observed in other tumor types.

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

Abstract

Discussion

Cite This Study

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

Abstract

Discussion

Cite This Study

Keep reading

Keep reading